The Cooper Companies COO · NASDAQ
$57.94 +0.94% (+$0.54)
Summary
51 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 13 USD is left as net profit.
- It beat profit estimates 8 times in the last 8 quarters.
What to watch
- The share price is above the Bulios Fair Price.
- It earns only 5.9 USD a year on every 100 USD of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 19.6 USD for 1 USD of yearly profit. Over the last five years it was 37.2 USD on average.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 11% a year over 5 years. Over the last 3 years it grew by 7.3% a year. For the next fiscal year analysts expect revenue to grow by 3.6%.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 35 USD
- Research and development 4.0 USD
- Sales and administration 47 USD
- Taxes and other -0.6 USD
- Net profit 13 USD
Net profit, industry median (Medical - Instruments & Supplies) 8.5 USD
Out of every 100 USD of revenue, 13 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 28.1 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 14
- Hold 13
- Sell 1
Today's price within the analysts' price targets
The average target of $65.75 is 13% above today's price. 50% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Coopervision Segment 67%
- Coopersurgical Segment 33%
By region
- UNITED STATES 46%
- Europe 40%
- Rest Of World, Excluding United States And Europe 13%
Coopervision Segment brings in 67% of revenue. Coopersurgical Segment grew fastest, by 15% a year.
Segments in detail